The combination of antiangiogenic therapy with other modalities

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Angiogenesis is crucial for physiological and pathological processes, including cancer development.
• Antiangiogenic therapy targets tumor blood vessel formation, showing potential benefits like reduced drug resistance and toxicity.
• Despite therapeutic promise, no angiogenesis inhibitor is currently approved for clinical use.

Purpose of the Study:

• To review the potential benefits and limitations of antiangiogenic therapy in cancer treatment.
• To explore strategies for optimizing antiangiogenic therapy, including combination approaches.
• To highlight the need for further understanding of antiangiogenic agents' mechanisms and regulation for clinical integration.

Main Methods:

• Review of preclinical and clinical trial data on angiogenesis inhibitors.
• Analysis of the mechanisms of action and regulation of antiangiogenic agents.
• Exploration of combination therapies involving antiangiogenic agents and other cancer treatments.

Main Results:

• Antiangiogenic agents offer potential advantages such as synergistic interactions and reduced toxicity compared to conventional therapies.
• Preclinical and early clinical data suggest a delayed onset of activity and potential disease stabilization rather than regression in advanced cancer.
• Differential regulation of angiogenesis across various capillary beds indicates a need for organ-specific optimization of antiangiogenic therapy.

Conclusions:

• Antiangiogenic therapy holds significant therapeutic potential for cancer, but clinical integration requires overcoming challenges related to delayed efficacy and disease stabilization.
• Combining antiangiogenic agents with each other or with other modalities may enhance efficacy and reduce toxicity.
• Further research into the mechanisms, regulation, and optimal clinical strategies for antiangiogenic agents is essential before widespread adoption in cancer treatment.